Conclusion
This study compared reoperation rates of CE Perimount and SJM Trifecta
aortic bioprostheses for AVR. The
rates of reoperation were comparable, with Trifecta showing higher rates
in patients younger than 60 years, and current smokers. Literature has
also shown that reoperation rates of Trifecta are comparable to
Perimount valves, with a few recent studies bringing into focus early
SVD in Trifecta, and increased midterm SVD in younger patients.
Continued diligence and further independent reporting of midterm
reoperation and SVD rates of the Trifecta, including detailed
echocardiographic follow up, are needed to confirm these findings.